In his latest Forbes article, WBB Securities President Dr. Steve Brozak examines the hidden dangers behind recent Medicaid funding cuts buried within a sweeping federal spending bill. Titled “Diagnosing Medicaid Cuts To Hospitals In The One Big Beautiful Bill”
Read More about Diagnosing Medicaid Cuts To Hospitals In The One, Big, Beautiful Bill – Published in ForbesWBB Securities today announced it had acted as the sole placement agent for a $9 million Series A funding round for FELIQS, a biotechnology company developing first-in-class small molecule therapeutics for rare pediatric retinal diseases.
Read More about WBB Securities acted as the sole placement agent for a $9 million Series A funding round for FELIQS
WBB Securities invites you to attend the upcoming Demy-Colton Virtual Salon titled:
“Seven Years After FDA Approval: What Have We Learned About Cell and Gene Therapies?”.
Dr. Steve Brozak, President of WBB Securities, has authored a new opinion piece in Forbes
Read More about President Donald Trump – Will He Become the Drug Price Equalizer?
WBB Securities is pleased to share a featured interview with our Managing Director, Dr. Steve Brozak, published in The Wall Street Transcript on April 29, 2025.
Read More about Onshoring Drug Manufacturing Is Critical But Not EasyPharmaceutical tariffs are looming again, and the stakes are higher than ever.
Read More about Pharma Dodges The Tariff Bullet—But For How Long?